MSD France
Division of Merck & Co. Inc.
www.msd-france.com
Latest From MSD France
Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round
Forbion Sees First Close Of New Biotech Fund At €270M In Record Time
With its 2015 third fund Forbion Capital III yielding an internal rate of about 65% and already returning 60% of the money it drew down back to investors, it is probably no surprise that Forbion exceeded its €250M target for its predominantly Europe-focused Forbion IV fund within two months of marketing.
Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications
Eight EU marketing authorization applications are up for an opinion this week from the CHMP, the European Medicines Agency committee that recommends whether or not products should be approved.
Roche 'Man In Bosnia' Works To Improve Cancer Drug Access, Faces High Hurdles
Adnan Filipovic has 'a sense of mission' to get cancer sufferers in Bosnia and Herzegovina access to innovative drugs despite the huge obstacles in that war-damaged country.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
France
-
France
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
- Michel Vounatsos, Managing Dir.
- Contact Info
-
MSD France
Phone: (33)
Paris,
France
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice